AHSCT versus high-efficacy DMTs in highly active MS: A perspective.

Bertolotto A, Valverde S

Open source

DOI
10.1177/13524585261472338
Published
2026 Aug 16
Container
Multiple sclerosis (Houndmills, Basingstoke, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/13524585261472338,
  title = {AHSCT versus high-efficacy DMTs in highly active MS: A perspective.},
  author = {Bertolotto A and Valverde S},
  year = {2026},
  journal = {Multiple sclerosis (Houndmills, Basingstoke, England)},
  doi = {10.1177/13524585261472338},
  url = {https://doi.org/10.1177/13524585261472338}
}

RIS

TY  - JOUR
TI  - AHSCT versus high-efficacy DMTs in highly active MS: A perspective.
AU  - Bertolotto A
AU  - Valverde S
PY  - 2026
JO  - Multiple sclerosis (Houndmills, Basingstoke, England)
DO  - 10.1177/13524585261472338
UR  - https://doi.org/10.1177/13524585261472338
ER  - 

APA

A, B., & S, V. (2026). AHSCT versus high-efficacy DMTs in highly active MS: A perspective.. Multiple sclerosis (Houndmills, Basingstoke, England). https://doi.org/10.1177/13524585261472338

Source records